NCT01222767 - Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Ewing's SarcomaPrimitive Neuroectodermal Tumor (PNET)Askin's Tumor of the Chest WallExtraosseous Ewing's Sarcoma (EOE)

Interventions

DRUG

Zalypsis

Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.

Trial Locations (7)

Istituto Clinico Humanitas, Rozzano

Istituto Nazionale dei Tumori, Milan

Istituto Ortopedici Rizzoli, Bologna

Centre Léon Bérard, Lyon

Sarcoma Oncology Center, Santa Monica

St. Jude Children 's Research Hospital, Memphis

Seattle Cancer Care Alliance, Seattle